0000000000082786

AUTHOR

Matthias Schneider

showing 7 related works from this author

Unexpected Conformational Behaviour of a Diphosphate Derived from a Spherand-Type Calixarene

2005

The spherand-type calixarene 2a, which consists of three diphenol units linked by methylene bridges, was treated with phosphorus pentachloride and then with water. A C1-symmetrical conformation was found for the resulting bisphosphate 7 in the crystalline state by X-ray analysis, with an anti orientation of the phosphoryl groups. MM3 calculations lead to a nearly identical conformation for the most stable isomer (RRS-twist), while a slightly higher energy was found for an RRS-crown isomer with a syn orientation of the phosporyl groups. Surprisingly, all NMR studies (1H, 13C and 31P) of 7 are in agreement with a dynamic C2 symmetry in solution. (© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Wein…

chemistry.chemical_compoundchemistryStereochemistryOrganic ChemistryCalixarenePhosphorus pentachloridePhysical and Theoretical ChemistryMethyleneEuropean Journal of Organic Chemistry
researchProduct

Effect of Process Parameters on the Joint Integrity in Friction Stir Welding of Ti-6Al-4V Lap Joints

2013

Friction Stir Welding (FSW) is a solid state welding process patented in 1991 by TWI; initially adopted to weld aluminum alloys, is now being successfully used also for magnesium alloys, copper and steels. The wide diffusion the process is having is due to the possibility to weld materials traditionally considered difficult to be welded or “unweldable” by traditional fusion welding processes due to peculiar thermal and chemical material properties. Additionally, the process allows welding a wide range of sheet thickness (up to 50mm) avoiding typical fusion welding processes defects, like cavities and porosities, with no shielding gas, filling material or joint preparation. Recently, researc…

Heat-affected zoneFiller metalMaterials scienceMechanical EngineeringMetallurgyShielding gasWeldingElectric resistance weldinglaw.inventionFusion weldingMechanics of MaterialslawGeneral Materials ScienceCold weldingFriction weldingComposite materialKey Engineering Materials
researchProduct

A framework for remission in SLE

2017

ObjectivesTreat-to-target recommendations have identified ‘remission’ as a target in systemic lupus erythematosus (SLE), but recognise that there is no universally accepted definition for this. Therefore, we initiated a process to achieve consensus on potential definitions for remission in SLE.MethodsAn international task force of 60 specialists and patient representatives participated in preparatory exercises, a face-to-face meeting and follow-up electronic voting. The level for agreement was set at 90%.ResultsThe task force agreed on eight key statements regarding remission in SLE and three principles to guide the further development of remission definitions:1. Definitions of remission wi…

Genetics and Molecular Biology (all)PediatricsAutoimmune diseasesNEPHRITIS PATIENTSDISEASE-ACTIVITYSeverity of Illness IndexBiochemistryRETROSPECTIVE ANALYSIS0302 clinical medicineQuality of lifePrednisoneAdrenal Cortex HormonesLupus Erythematosus SystemicImmunology and AllergyCHINESE PATIENTS030212 general & internal medicineSYSTEMIC-LUPUS-ERYTHEMATOSUSskin and connective tissue diseasesPREDICTORSOUTCOMESSystemic lupus erythematosusMalalties autoimmunitàriesRemission InductionSYSTEMIC-LUPUS-ERYTHEMATOSUS; DISEASE-ACTIVITY; RETROSPECTIVE ANALYSIS; INITIAL VALIDATION; NEPHRITIS PATIENTS; AMERICAN-COLLEGE; CHINESE PATIENTS; RENAL FLARES; PREDICTORS; OUTCOMESSymptom Flare UpConnective tissue diseaseManchester Institute for Collaborative Research on AgeingEstudi de casosOutcomes researchAntibodies AntinuclearDNA/immunologyImmunosuppressive Agentsmedicine.drugmedicine.medical_specialtyFarmacologiaResearchInstitutes_Networks_Beacons/MICRAConsensusImmunologyAdrenal Cortex Hormones/therapeutic useAMERICAN-COLLEGELupus Erythematosus Systemic/bloodSystemic Lupus ErythematosusGeneral Biochemistry Genetics and Molecular BiologyMaintenance Chemotherapy03 medical and health sciencesAntimalarialsRheumatologySeverity of illnessmedicineDisease Activity; Outcomes research; Systemic Lupus Erythematosus; Immunology and Allergy; Rheumatology; Immunology; Biochemistry Genetics and Molecular Biology (all)HumansDisease Activity030203 arthritis & rheumatologyPharmacologyAntibodies Antinuclear/bloodLupus erythematosusbusiness.industryTask forceConstruct validityRENAL FLARESComplement System ProteinsDNAINITIAL VALIDATIONDisease Activity; Outcomes research; Systemic Lupus Erythematosusmedicine.diseaseLupus eritematósAntimalarials/therapeutic usePhysical therapyImmunosuppressive Agents/therapeutic useComplement System Proteins/metabolismCase studiesOutcomes researchbusinessAnnals of the Rheumatic Diseases
researchProduct

Impact of switching from mycophenolate mofetil to enteric-coated mycophenolate sodium on gastrointestinal side effects in patients with autoimmune di…

2015

Bernhard Manger,1 Falk Hiepe,2 Matthias Schneider,3 Margitta Worm,4 Peter Wimmer,5 Eva-Maria Paulus,5 Andreas Schwarting6 1University Hospital Erlangen, Med Clinic III Polyclinic, Erlangen, 2Rheumatology, University Hospital Charité, Campus Mitte, Berlin, 3Policlinic of Rheumatology, Heinrich-Heine-Universität, Düsseldorf, 4Department of Dermatology, Venereology and Allergology, University Hospital Charité, Campus Mitte, Berlin, 5Novartis Pharma GmbH, Nürnberg, 6Department of Internal Medicine, Johannes Gutenberg University, Mainz, Germany Background: The purpose of this study was to assess changes in gastrointestinal symptom severity in pati…

medicine.medical_specialtyAbdominal painClinical and Experimental GastroenterologyNauseabusiness.industrymycophenolate mofetilGastroenterologyautoimmune diseaseenteric-coated mycophenolate sodiumpatient-reported outcomeIndigestionhealth-related quality of lifeQuality of lifeRating scaleInternal medicineClinical endpointmedicinePatient-reported outcomemedicine.symptomAdverse effectbusinessOriginal ResearchClinical and Experimental Gastroenterology
researchProduct

Compact embeddings and indefinite semilinear elliptic problems

2002

Our purpose is to find positive solutions $u \in D^{1,2}(\rz^N)$ of the semilinear elliptic problem $-\laplace u = h(x) u^{p-1}$ for $2<p$. The function $h$ may have an indefinite sign. Key ingredients are a $h$-dependent concentration-compactness Lemma and a characterization of compact embeddings of $D^{1,2}(\rz^N)$ into weighted Lebesgue spaces.

Lemma (mathematics)Pure mathematicsLaplace transformFunction spaceApplied MathematicsWeak solutionMathematical analysisFunction (mathematics)Functional Analysis (math.FA)Mathematics - Functional AnalysisElliptic curveMathematics - Analysis of PDEsFOS: Mathematics35J65 35D05Lp spaceAnalysisAnalysis of PDEs (math.AP)Sign (mathematics)Mathematics
researchProduct

Micro and macro mechanical characterization of friction stir welded Ti–6Al–4V lap joints through experiments and numerical simulation

2013

Abstract Lap joints of Ti–6Al–4V were produced and the effect of the main process parameters was studied through macro and micro investigations highlighting mechanical resistance, microhardness profiles, grain size and phase distributions. A dedicated numerical model was used to link the input process parameters to temperature and strain distributions and to the final microstructure in the welded joint. It is found that the strain produced in the stir zone by proper combination of process parameters plays a fundamental role in the final microstructure and mechanical properties of the joints.

FEMMaterials scienceFriction stir weldingLap jointsMetallurgyMetals and AlloysTitanium alloyWeldingMicrostructureIndentation hardnessIndustrial and Manufacturing EngineeringGrain sizeComputer Science Applicationslaw.inventionLap jointlawModeling and SimulationCeramics and CompositesFriction stir weldingTitanium alloyComposite materialJoint (geology)Journal of Materials Processing Technology
researchProduct

BIOM-08. DNA METHYLATION-BASED SUBGROUPING PREDICTS SURVIVAL BENEFIT FROM LOMUSTINE/TEMOZOLOMID COMBINATION THERAPY IN MGMT PROMOTOR-METHYLATED GLIOB…

2021

Abstract BACKGROUND The CeTeG/NOA-09 trial showed that lomustine/temozolomide chemotherapy prolongs survival for newly diagnosed MGMT-methylated glioblastoma patients. Previous reports on temozolomide monotherapy suggested, that the survival benefit of temozolomide in MGMT-methylated tumors may be restricted to the RTK II methylation subgroup and absent in RTK I and MES subgroups. To identify patients with a particularly strong benefit from CCNU/TMZ, we explored the association of methylation subgroups with outcome after lomustine/temozolomide therapy. METHODS All patients from the CeTeG/NOA-09 trial with sufficiently available tumor tissue (n = 98) underwent 850K methylation array analysis…

Cancer ResearchCombination therapybusiness.industryMedizinPromoterLomustine26th Annual Meeting & Education Day of the Society for Neuro-Oncologymedicine.diseaseSurvival benefitOncologyDNA methylationmedicineCancer researchNeurology (clinical)Temozolomidbusinessmedicine.drugGlioblastomaNeuro-Oncology
researchProduct